Buradasınız

Anasayfa » Content

Mesane transizyonel hücreli karsinomunun transüretral rezeksiyon sonrası takibinde NMP22 testinin etkinliği ve güvenilirliği

The efficacy and the safety of the NMP22 test in the follow-up of urinary bladder transitional cell carcinoma after transurethral resection

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
This study has been prepared to evaluate the efficacy of NMP22 test in the followup of recurrent bladder transitional cell carcinoma and to compare it with urine cytology used to assist to cystoscopy. Urine samples voided prior to cystoscopic examination were collected from 94 patients who were in the follow-up program for superficial bladder cancer, and stabilized in the NMP22 urine collection kit. During the cystoscopic examination, the bladder cleaning sample for cytologic examination was taken by irrigating the bladder, and it was stabilized by the ethyl alcohol until cytopathologic analysis. Urines of those who had recurrent tumors had significantly higher NMP22 levels than those of those who did not have recurrent tumors (p<0.001). When reference value of 10 U/ml was used in NMP22 test, the sensitivity, specificity, positive predictive value and negative predictive value were 73.8%, 82.7%, 77.5% and 79.6%, respectively. The sensitivity and specificity of urine cytology were 52.4% and 90.4%, respectively. The sensitivity of NMP22 test was significantly higher than that of urine cytology in tumors with low grade and stage. Although the sensitivity and negative predictive value of NMP22 test were significantly higher than those of urine cytology in bladder transitional cell carcinomas, especially with low grade and stage, it should be evaluated as a complemantary test to cytology rather than taking place of it as an assistant method to cystoscopy since it does not have sufficient specificity.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada nüks mesane transizyonel hücreli karsinomaların takibinde NMP22 testinin etkinliğini değerlendirmek ve bu amaçla sistoskopiye yardımcı olarak kullanılan idrar sitolojisi ile karşılaştırmak amaçlanmıştır. Yüzeyel mesane kanseri nedeniyle takip edilen 94 hastadan sistoskopik inceleme öncesi işenmiş idrar örneği alınarak, NMP22 idrar toplama kitinde stabilize edildi. Sitolojik inceleme için ise sistoskopik inceleme sırasında, mesane irrige edilerek mesane yıkama örneği alındı ve etil alkolle stabilize edilerek sitopatolojik analiz uygulandı. Nüks tümörü olanların olmayanlara göre idrar NMP22 düzeyinde anlamlı yükseklik olduğu gözlendi (p<0.001). NMP22 testinde 10 U/ml referans değeri olarak kullanıldığında sensitivite %73.8, spesifisite %82.7, pozitif öngörü değeri %77.5, negatif öngörü değeri ise %79.6 olarak bulunmuştur. İdrar sitolojisinin sensitivitesini %52.4, spesifisitesini ise %90.4 olarak bulduk. Düşük "grade" ve "stage" tümörlerde NMP22 testinin sensitivite oranlarının sitolojiden belirgin olarak yüksek olduğu görüldü. NMP22 testinin transizyonel hücreli mesane karsinomunda, özellikle düşük "grade" ve "stage" tümörlerde gösterdiği yüksek sensitivite ve negatif öngörü değerleri idrar sitolojisinden bariz üstün olmakla beraber, spesifisitedeki yetersizliğinden dolayı, sistoskopiye yardımcı bir metod olarak sitolojinin yerini almaktan ziyade, birbirini tamamlayan testler olarak değerlendirilmelidir.
FULL TEXT (PDF): 
PDF icon arastirmax-mesane-transizyonel-hucreli-karsinomunun-transuretral-rezeksiyon-sonrasi-takibinde-nmp22-testinin-etkinligi-guvenilirligi.pdf
  • 1
14-20
  • Turkish

REFERENCES

References: 

1. Edward M, Messing EM. Urothelial
tumors of the urinary tract. In: Walsh
R, Vaughan W (Eds) Campell's Urology. 8th ed. Vol.4. 2002: 2732-2784.
2. Lee R, Droller MJ. The natural history of bladder cancer. Implications for
therapy. Urol Clin North Am 2000;
27: 1-13.
3. Oge O, Erdem E, Atsu N, et al.
Proposal for changes in cystoscopic
follow-up patients with low-grade pTa
bladder tumor. Eur Urol 2000; 37:
271-274.
4. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 2000; 90: 75-
86.
5. Brown FM. Urine cytology. It is still
the gold standart for screening? Urol
Clin North Am 2000; 27: 25-37.
6. Konety BR, Getzenberg RH. Urine
based markers of urological malignancy. J Urol 2001; 165: 600-611.
7. Koenig F, Jung K, Schnorr DL, et al.
Urinary markers of malignancy. Clin
Chim Acta 2000; 297: 191-205.
8. Sharma S, Zippe CD, Pandrangi L, et
al. Exclusion criteria the specifity and
positive predictive value of NMP22
and BTA stat. J Urol 1999; 162: 53-57.
9. Sawczuk IH, Lee B. The mechanism
and clinical applications of the
NMP22 tumor marker immunoassay:20 · Mart 2007 · Gülhane TD Saðnak ve ark.
a review. Am Clin Lab 1999; 18: 24-26.
10.Stampfer DS, Carpinito GA, Rodrigez-Villanueva J, et al. Evaluation of
NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol
1998; 159: 394-398.
11.Morris SB, Shearer RJ, Gordon EM,
Woodhouse CR. Superficial bladder
cancer: timing of check cystoscopies in
the first year. Br J Urol 1993; 72: 446-
448.
12.Meyhoff HH, Andersen JT, Klarskov
P, et al. Flexible fiberoptic versus conventional cystourethroscopy in bladder tumor patients: a prospective
study. Scand J Urol Nephrol 1988;
110: 237-240.
13.Koshikawa T, Leyk H, Schenck U.
Difficulties in evaluating urinary specimens after local mitomycin therapy of
bladder cancer. Diagn Cytopathol
1989; 5: 117-121.
14.Sarosdy MF, White RW, Soloway MS,
et al. Results of a multicenter trial
using the BTA test to monitor for and
diagnose recurrent bladder cancer. J
Urol 1995; 154: 379-383.
15.Sagerman PM, Saigo PE, Sheinfeld
MD, et al. Enhanced detection of bladder cancer in cytology with Lewis X,
M344 and 19A211 antigens. Acta
Cytologica 1994; 38: 517-523.
16.Sanchez-Carbayo M, Urrutia M,
Hernandez-Cerceno ML, Gonzales de
Buitrago JM, Navajo JA. Cytokeratins
(UBC and CYFRA 21-1) and nuclear
matrix proteins (NMP22) as urine
tumor markers in the diagnosis of
bladder cancer. Med Clin (Barc) 2000;
114: 361-366.
17.Miyanaga N, Akaza H, Tsukamoto T,
et al. Urinary nuclear matrix protein
22 as a new marker for the screening of
urothelial cancer in patients with
microscopic hematuria. Int J Urol
1999; 6: 173-177.
18.Menendez V, Filella X, Alcover JA, et
al. Usefulness of urinary Nuclear
Matrix Protein 22 (NMP22) as a
marker for transitional cell carcinoma
of the bladder. Anticancer Res 2000;
20 (2B): 1169-1172.
19.Landman J, Chang Y, Kavaler E, et al.
Sensitivity and specificity of NMP22,
telomeraz, and BTA in the detection
of human bladder cancer. Urology
1998; 52: 398-402.
20.Miyanaga N, Akaza H, Ishikawa S, et
al. Clinical evaluation of nuclear
matrix protein 22 (NMP22) in urine
as a novel marker for urothelial cancer.
Eur Urol 1997; 31: 163-168.
21.Pirtskalaishvili G, Konety BR,
Getzenberg RH. Update on urinebased markers for bladder cancer.
How sensitive and specific are the new
noninvasive tests? Postgrad Med 1999;
106: 85-86, 91-94.
22.Casella R, Huber P, Blochlinger A, et
al. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with
biopsy confirmed tumor. J Urol 2000;
164: 1926-1928.
23.Serretta V, Pomara G, Rizzo I, et al.
Urinary BTA-stat and NMP22 in surveillance after TUR of recurrent
superficial transitional cell carcinoma
of the bladder. Eur Urol 2000; 38:
419-425.
24.Del Nero A, Esposito N, Curro A, et
al. Evaluation of urinary level of
NMP22 as a diagnostic marker for
stage pTa-T1 bladder cancer: comparison with urinary cytology and BTA
test. Eur Urol 1999; 35: 93-97.
25.Sanchez-Carbayo M, Herrero E, et al.
Evaluation of nuclear matrix protein
22 as a marker in the detection of transitional cell carcinoma of the bladder.
BJU Int 1999; 84: 706-713.
26.Soloway MS, Briggman V, Carpinito
GA, et al. Use of a new tumor marker,
urinary NMP22, in the detection of
occult or rapidly recurring transitional
cell carcinoma of the urinary tract following surgical treatment. J Urol
1996; 156: 363-367.
27.Casetta G, Gontero P, Zitella A, et al.
BTA quantitative assay and NMP22
testing compared with urine cytology
in the detection of transitional cell carcinoma of the bladder. Urol Int 2000;
65: 100-105.
28.Akaza H, Miyanaga N, Tsukamoto T,
et al. Evaluation of urinary NMP22
(Nuclear Matrix Protein 22) as a diagnostic marker for urothelial cancerscreening for urothelial cancer in patients with microscopic hematuria-.
Gan To Kagaku Ryoho 1997; 24: 829-
836.
29.Zippe C, Pandrangi L, Potts JM, et al.
NMP22: a sensitive, cost-effective test
in patients at risk for bladder cancer.
Anticancer Res 1999; 19: 2621-2623.
30.Carpinito GA, Stadler WM, Briggman
JV, et al. Urinary nuclear matrix protein as a marker for transitional cell
carcinoma of the urinary tract. J Urol
1996; 156: 1280-1285.
31.Zippe C, Pandrangi L, Agarwal A.
NMP22 is a sensitive, cost-effective
test in patients at risk for bladder cancer. J Urol 1999; 161: 62-65.
32.Sozen S, Biri H, Sýnýk Z, et al.
Comparison of the nuclear matrix
protein 22 with voided urine cytology
and BTA stat test in the diagnosis of
transitional cell carcinoma of the bladder. Eur Urol 1999; 36: 225-229.
33.Shelfo SW, Soloway MS. The role of
nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.
World J Urol 1997; 15: 107-111.
34.Perez Garcia FJ, Escaf Barmadah S,
Fernandez Gomez JM, Rodriguez
Martinez JJ, Martin Benito JL.
Determination of NMP22 as recurrence marker in bladder cancer.
Preliminary study. Arch Esp Urol
2000; 53: 305-312.
35.Ramakumar S, Bhuiyan J, Besse JA, et
al. Comparison of screening methods
in the detection of bladder cancer. J
Urol 1999; 161: 388-394.
36.Gutierrez Banos JL, Rebollo Rodrigo
MH, et al. NMP22 in the diagnosis of
bladder cancer. Actas Urol Esp 2000;
24: 715-720.

Thank you for copying data from http://www.arastirmax.com